Compare ARK Innovation ETF (ARKK) vs Baxter International Inc (BAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Innovation ETF vs Baxter International Inc — how do they compare? ARK Innovation ETF trades at $79.65, while Baxter International Inc trades at $22.08 (market cap $11.68B). The key difference: Baxter International Inc pays a 0.88% dividend while ARK Innovation ETF pays none. Which is the better fit depends on your goals.
| ARKK | BAX | |
|---|---|---|
52-Week High | $92.50 | $29.22 |
52-Week Low | $63.52 | $15.80 |
Market Cap | — | $11.68B |
Sector | — | Health |
Enterprise Value | — | $19.35B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $80.25, down 1.58% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF has gained about 2% year-to-date through late June, sitting near its pivot point of $81. Recent news highlights Cathie Wood's continued stock purchases during pullbacks while the fund faces criticism for its 0.75% expense ratio and underperformance relative to broader tech markets.
The outlook remains mixed with strong technical momentum but fundamental concerns about fees and concentrated exposure to volatile innovation stocks. Key risks include Tesla's 10% weighting creating single-stock vulnerability and the fund's history of 37.88% losses over five years despite recent investor interest resurgence.
Baxter International (BAX) trades at $22.62, up 0.71% on the day, near the consensus price target of $22.67. The stock shows a bullish technical trend with recent earnings beats in Q1 2026, though profitability remains challenged with negative net income margins. Recent news highlights sustainability initiatives and upcoming Q2 2026 earnings, with analyst sentiment mixed but leaning hold.
Outlook hinges on operational turnaround amid margin pressures; upside exists if cost controls and innovation boost profits, but high debt and inconsistent cash flow pose risks. The stock offers speculative value for patient investors betting on recovery, but near-term volatility is likely until earnings stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →
